OBJECTIVES: The aim of this study was to assess the predictive value of survival in patients with advanced non-small cell lung cancer (NSCLC) treated with cisplatin-based first-line chemotherapy. METHODS: In this study, 138 consecutive patients with advanced NSCLC were included in this study. Glasgow prognostic score (GPS) was calculated before the onset of treatment. The outcome indicators were progression free survival (PFS) and overall survival (OS). RESULTS: Univariate log-rank test showed that GPS was significantly associated with both PFS (P = 0.01) and OS (P = 0.02). Multivariate Cox model revealed that the hazard ratios (HRs) for PFS were 0.8(0.5-0.9) for GPS 1 versus GPS 0 and 0.5(0.3-0.8) for GPS 2 versus GPS 0, respectively. The HRs for OS were 0.8(0.4-0.9) for GPS 1 versus GPS 0 and 0.5(0.2-0.8) for GPS 2 versus GPS 0, respectively. CONCLUSIONS: The GPS can be used as an independent predictor for survival in patients with advanced NSCLC.
OBJECTIVES: The aim of this study was to assess the predictive value of survival in patients with advanced non-small cell lung cancer (NSCLC) treated with cisplatin-based first-line chemotherapy. METHODS: In this study, 138 consecutive patients with advanced NSCLC were included in this study. Glasgow prognostic score (GPS) was calculated before the onset of treatment. The outcome indicators were progression free survival (PFS) and overall survival (OS). RESULTS: Univariate log-rank test showed that GPS was significantly associated with both PFS (P = 0.01) and OS (P = 0.02). Multivariate Cox model revealed that the hazard ratios (HRs) for PFS were 0.8(0.5-0.9) for GPS 1 versus GPS 0 and 0.5(0.3-0.8) for GPS 2 versus GPS 0, respectively. The HRs for OS were 0.8(0.4-0.9) for GPS 1 versus GPS 0 and 0.5(0.2-0.8) for GPS 2 versus GPS 0, respectively. CONCLUSIONS: The GPS can be used as an independent predictor for survival in patients with advanced NSCLC.